Clinical Trial Update: A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers [Phase 1]

View source ↗

Summary

Nuvectis Pharma reports a Phase 1 clinical trial of NXP-900 in subjects with advanced cancers is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• Solid Tumors

Drugs mentioned

• NXP-900

Snippet

Sponsor: Nuvectis Pharma, Inc. | Conditions: Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer) | Phase 1 | Status: RECRUITING